CPHI Stock Analysis: Buy, Sell, or Hold?
CPHI - China Pharma Holdings, Inc.
$0.64
-0.06 (-7.93%)
▼
5d:
-18.17%
30d:
-15.76%
90d:
+8.81%
WAIT
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When CPHI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CPHI is down 18.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CPHI is down 18.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CPHI is currently trading at $0.64, which is considered oversold relative to its 30-day fair value range of $0.71 to $0.81.
Technical Outlook: Technically, CPHI is showing sideways momentum. The price is currently testing key support at $0.71. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.00 (+368.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CPHI is showing sideways momentum. The price is currently testing key support at $0.71. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.00 (+368.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.71 -
$0.81
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.9%)
- BULLISH: Trading 368.7% below Wall St target ($3.00)
- WARNING: Recommendation downgraded due to -18.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.71 -
$0.81
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.71
Resistance Level
$0.90
Current Trend
Sideways
Technical data as of
Jun 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.56
Wall Street Target
$3.00
(+368.7%)
Revenue Growth (YoY)
-13.4%
Profit Margin
-88.8%
Share & Embed Analysis
Last updated: June 24, 2026 7:37 PM ET
Data refreshes hourly during market hours. Next update: 8:37 PM
Data refreshes hourly during market hours. Next update: 8:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CPHI showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 59 HOLD |
